World-First Korean Nod For Hanmi's Neutropenia Contender Rolontis
US Pre-Approval Inspection Bodes Well?
Hanmi’s novel, long-acting neutropenia drug gets world-first approval in South Korea, setting it up to be the first product using the company's proprietary platform technology to be commercialized. An FDA manufacturing inspection also seems to bode well for the pending US approval.
